This clinical trial is focused on studying the treatment of rheumatoid arthritis, a condition that causes pain and swelling in the joints. The study will compare the effects of a proposed biosimilar called DRL_AB with an existing medication known as Orencia, both of which are given through an intravenous infusion. These treatments will be used alongside another medication called methotrexate, which is commonly used to manage rheumatoid arthritis.
The purpose of the study is to evaluate how effective and safe these treatments are, as well as to understand their impact on the immune system. Participants will receive either the biosimilar or Orencia, in addition to methotrexate, over a period of time. The study will monitor changes in the participants’ condition, particularly focusing on improvements in joint pain and swelling, as well as any side effects that may occur.
Throughout the study, participants will have regular check-ups to assess their response to the treatment. The study aims to provide valuable information on whether the new biosimilar is as effective and safe as the existing treatment option, Orencia, for people with moderate to severe rheumatoid arthritis. This research could potentially offer more treatment choices for managing this chronic condition.
Bulgaria 
Czechia 
Estonia 
Hungary 
Latvia 
Lithuania 
Poland 
Romania 
